RepliCel Announces Material Patent Milestones in Key Markets
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key marketsVANCOUVER, BC / ACCESSWIRE / August 4, 2022 / RepliCel Life Sciences Inc. (OT
AccesswireAug 4, 2022 06:05 ET
DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections
Independent Testing Performed by Innovacell Demonstrates the DermaPrecise™ Control Leads to Unparalleled Post-Injection Cell Survival and Viability ConsistencyVANCOUVER, BC / ACCESSWIRE / August 2, 20
AccesswireAug 2, 2022 06:05 ET
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
This press release replaces the press release disseminated July 26, 2022 at 06:00 EDT. The press release contained the wrong image - one intended for a future press release. The corrected press releas
AccesswireJul 26, 2022 16:50 ET
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissueVANCOUVER, BC / ACCESSWIRE / July 26, 2022
AccesswireJul 26, 2022 06:05 ET
RepliCel Announces Material Patent Milestones
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key marketsVANCOUVER, BC / ACCESSWIRE / January 10, 2022 / RepliCel Life Sciences Inc. (
AccesswireJan 10, 2022 06:06 ET
RepliCel Closed Final Tranche of Strategic Investment Commitment
VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in a
AccesswireDec 21, 2021 17:06 ET
RepliCel Terminates License Agreement with Shiseido
VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aes
AccesswireDec 21, 2021 11:16 ET
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
Kunihiko Suzuki, one of the leading pioneers in Japan's emerging regenerative medicine industry, commits to a role as Senior Strategic Advisor to RepliCel's Board of DirectorsVANCOUVER, BC / ACCESSWIR
AccesswireOct 11, 2021 18:00 ET
No Data
No Data